Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma

NCT05890352 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT05890352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05890352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Recruiting
Start date
September 26, 2023
Completion date
January 31, 2029
Enrollment
227 (estimated)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

grade 3b follicular lymphoma, high grade b-cell lymphoma, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, recurrent diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, transformed non-hodgkin lymphoma